Earnings
CRSP
199.88
-4.84%
-10.16
Currencies: USD
Items
Net Income
Depreciation and Amortization
Deferred Tax
Unamortized Expenditures
Accrued Expenses
Share-based Compensation
Assets Disposal
Financial Expenses
Investment Loss
Working Capital Change
Other Items
Operating Activities
Purchases of Fixed Assets
Proceeds from Disposal of Fixed Assets
Investment Expenditure
Investment Income
Other Investing Activities
Investing Activities
Issuance of Capital Stock
Issuance of Bonds
Proceeds from Borrowings
Dividend Payments
Repayment of Borrowings
Buyback Payments
Stock Incentive Compensation
Other Financing Activities
Financing Activities
Effect of Exchange Rate Changes 
Net Increase in Cash,Cash Equivalents
FY 2019-12-31
66.86M
4.72M
--
--
--
--
33.52M
--
--
-48.43M
--
56.68M
-6.68M
--
--
--
8.01M
1.32M
430.98M
--
--
--
--
--
--
--
430.98M
15.00K
489.00M
FY 2018-12-31
-164.98M
3.52M
--
--
--
--
54.67M
--
--
10.55M
--
-96.24M
-2.77M
--
--
--
0.00
-2.77M
315.93M
--
--
--
--
--
--
--
315.93M
-22.00K
216.90M
FY 2017-12-31
-68.36M
3.02M
--
--
--
--
20.63M
--
--
-25.39M
--
-70.10M
-7.81M
--
--
--
-500.00K
-8.31M
2.61M
0.00
--
--
--
--
--
--
2.61M
41.00K
-75.76M
FY 2016-12-31
-23.20M
925.00K
--
--
--
--
-34.81M
--
--
1.78M
--
-55.31M
-3.02M
--
--
--
34.90M
31.88M
115.02M
35.01M
--
--
--
--
--
--
183.22M
-235.00K
159.56M
FY 2015-12-31
-25.83M
127.00K
--
--
--
--
3.76M
--
--
81.37M
--
59.43M
-1.15M
--
--
--
0.00
-1.15M
58.86M
38.24M
--
--
--
--
--
--
96.73M
9000.00
155.02M

FY: Financial Year. It represents annual report.

Q: Quarter Report. Q1、Q2、Q3、Q4 represent three-month periodic financial reports.

Check out CRSP latest annual and quarterly financial reports. There are also historical financial reports for you to reference. You can analyze Crispr Therapeut recent business situations by check its cash flow statements, balance sheets, income statements and other tables. Comprehensive data may help you to understand and analyze CRSP development prospects in various aspects, and this information may help you to better grasp the Crispr Therapeut operation.